by Shayla Love | Statnews.com
“The leading treatment for prostate cancer may, in the longer term, increase a person’s risk for dementia, a new study finds.
A section of a human brain with Alzheimer’s disease is on display at the Museum of Neuroanatomy at the University at Buffalo, in Buffalo, N.Y., Oct. 7, 2003. (AP Photo/David Duprey)
“The retrospective study, published in JAMA Oncology Thursday, analyzed almost a decade’s worth of medical records and found that men with prostate cancer who are treated with androgen deprivation therapy (ADT) are twice as likely to develop dementia, including Alzheimer’s, within five years, compared to prostate cancer patients who do not receive testosterone-lowering therapies.”